Plexus Reports Strong Q1 Revenue & EPS Growth Amidst Cash Flow Challenges
summarizeSummary
Plexus Corp. reported strong first-quarter revenue and EPS growth, but experienced a notable decline in operating and free cash flow, driven by increased working capital needs.
check_boxKey Events
-
Strong Revenue and EPS Growth
Net sales increased 9.6% to $1.07 billion, and diluted earnings per share (EPS) rose 12.7% to $1.51 for the quarter ended January 3, 2026, compared to the prior year period.
-
Significant Cash Flow Deterioration
Cash flow from operating activities shifted from a positive $53.6 million to a negative $15.4 million, and free cash flow turned negative at $(50.6) million, primarily due to increased inventory and accounts receivable.
-
Ongoing Share Repurchase Program
The company repurchased $22.4 million of common stock under its $100 million 2026 program, with $62.6 million of authority remaining as of January 3, 2026.
-
CEO Adopts 10b5-1 Trading Plan
President and CEO Todd Kelsey adopted a Rule 10b5-1 trading arrangement on November 20, 2025, to sell up to 23,231 shares through February 18, 2027, providing context to recent insider selling activity.
auto_awesomeAnalysis
Plexus Corp.'s latest 10-Q reveals a mixed financial picture, with robust top-line and bottom-line growth offset by a significant deterioration in cash flow. While the company achieved a 9.6% increase in net sales and a 12.7% rise in diluted EPS, cash flow from operating activities turned negative, primarily due to increased inventory and accounts receivable. This cash consumption for growth, coupled with the CEO's adoption of a 10b5-1 selling plan and other recent insider sales, warrants investor attention, especially as the stock trades near its 52-week high. The company's ongoing share repurchase program is a positive signal of capital allocation, but the liquidity dynamics will be a key area for investors to monitor in upcoming quarters.
At the time of this filing, PLXS was trading at $201.07 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $5.4B. The 52-week trading range was $103.43 to $208.92. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.